ALK and non-small cell lung carcinoma: In an attempt to further improve the survival prognosis of patients with ALK rearranged NSCLC lung cancer, monoclonal antibodies against ALK related proteins are in a pipeline and have demonstrated certain efficacy in preclinical studies.